Develops therapies for cancer and autoimmune diseases, focusing on artificial antigen-presenting cells and immunotherapies.
NexImmune, Inc. is a dynamic clinical-stage biotechnology company focused on pioneering therapies with potential curative effects for patients battling cancer and severe immune-mediated diseases. Central to its innovative approach is the development of T cell immunotherapies leveraging its proprietary Artificial Immune Modulation nanoparticle technology platform.
At the forefront of NexImmune's pipeline are several promising product candidates. NEXI-001, an allogeneic cell therapy, is currently advancing through Phase I/II clinical trials aimed at treating patients with acute myeloid leukemia. Similarly, NEXI-002, an autologous cell therapy, is in Phase I/II trials targeting individuals with relapsed and/or refractory multiple myeloma. Additionally, the company is developing NEXI-003, a candidate designed to combat HPV-associated malignancies, currently in the preclinical stage of development.
Founded in 2011 and headquartered in Gaithersburg, Maryland, NexImmune continues to push boundaries in biotechnology innovation. With a steadfast commitment to advancing transformative therapies, the company is poised to make significant strides in improving outcomes for patients confronting challenging and life-threatening conditions globally.